Atlas Trials

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Clinical trial NCT07104032 · RECRUITING

Trial details

NCT number
NCT07104032
Sponsor
Ono Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed/Refractory Primary Central Nervous System Lymphoma
Start date
2026-06-12
Primary completion
2027-12-01
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.